Assessment of Heritable Genetic Effects Using New Genetic Tools and Sentinels in an Era of Personalized Medicine

被引:2
|
作者
Elespuru, Rosalie K. [1 ]
机构
[1] US FDA, Div Biol, Off Sci & Engn Labs, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA
关键词
germ cell mutations; personalized medicine; heritable genetic disease; birth defects monitoring; sentinel mutations; CYSTIC-FIBROSIS GENE; CHILDHOOD-CANCER; BIRTH-DEFECTS; CONGENITAL-MALFORMATIONS; PATERNAL SMOKING; PARENTAL SMOKING; POSTGENOME ERA; TOBACCO-SMOKE; FACTOR-IX; MUTATION;
D O I
10.1002/em.20637
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
The challenge of estimating human health effects from damage to the germ line may be met in the genomic era. Understanding the genetic, as opposed to postconception developmental basis of birth defects is critical to their use in monitoring heritable genetic damage. The causes of common birth defects are analyzed here: mendelian genetic, multigenic, developmental, inherited, or combinational. Only a small fraction of these (noninherited, mendelian genetic) are likely to be informative relative to germ cell mutagenesis, and these won't be discernible against the general background of birth defects. Targeted genetic testing as part of personalized medicine could be integrated into a strategy for assessing germ cell alterations in populations. Thus, "sentinel mutations,'' as originally proposed by Mulvihill and Ceizel, need not be restricted to X-linked or dominant mutations or conditions visible at birth. Several new sentinels related to personalized medicine are proposed, based on health impact (likelihood of monitoring), frequency, and genetic target suitability (responsiveness to diverse mutational mechanisms). Candidates could include CYP genes (related to metabolism of xenobiotics) important in optimizing drug doses and avoiding adverse reactions. High frequency LDLR mutations (related to familial high cholesterol) predict myocardial infarction in similar to 50% of individuals. The more common recessive genetic diseases (cystic fibrosis, phenylketonuria, and others) monitored in newborn screening programs could be informative given parental analysis. New opportunities for genetic analyses need to be coupled with epidemiological studies on environmental exposures. These could focus on adverse outcomes related to tobacco, the most ubiquitous and potent environmental mutagen. Environ. Mol. Mutagen. 52:253-263, 2011. Published 2011 Wiley-Liss, Inc.(dagger)
引用
收藏
页码:253 / 263
页数:11
相关论文
共 50 条
  • [31] Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients
    Goulielmos, George N.
    Zervou, Maria I.
    Myrthianou, Effie
    Burska, Agata
    Niewold, Timothy B.
    Ponchel, Frederique
    [J]. GENE, 2016, 583 (02) : 90 - 101
  • [32] Reproductive Genetic Testing and Human Genetic Variation in the Era of Genomic Medicine
    Lowther, Chelsea
    Costain, Gregory
    Bassett, Anne S.
    [J]. AMERICAN JOURNAL OF BIOETHICS, 2015, 15 (06): : 25 - 26
  • [33] A new era of genetic diversity conservation through novel tools and accessible data
    Hunter, Margaret E.
    da Silva, Jessica M.
    Mastretta-Yanes, Alicia
    Hoban, Sean M.
    [J]. FRONTIERS IN ECOLOGY AND THE ENVIRONMENT, 2024, 22 (04)
  • [34] Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin
    McWilliam, Andrew
    Lutter, Randall
    Nardinelli, Clark
    [J]. PERSONALIZED MEDICINE, 2008, 5 (03) : 279 - 284
  • [35] Assessment of genetic variation in a collection of lentil using molecular tools
    Gabriella Sonnante
    Domenico Pignone
    [J]. Euphytica, 2001, 120 : 301 - 307
  • [36] Assessment of genetic variation in a collection of lentil using molecular tools
    Sonnante, G
    Pignone, D
    [J]. EUPHYTICA, 2001, 120 (02) : 301 - 307
  • [37] Personalized medicine and allergen immunotherapy: the beginning of a new era?
    Cristoforo Incorvaia
    Erminia Ridolo
    Diego Bagnasco
    Silvia Scurati
    Giorgio Walter Canonica
    [J]. Clinical and Molecular Allergy, 19 (1)
  • [38] The new era of personalized medicine: 10 years later
    Jorgensen, Jan Trost
    Winther, Henrik
    [J]. PERSONALIZED MEDICINE, 2009, 6 (04) : 423 - 428
  • [39] PHARMACOGENOMICS: TOWARDS A NEW ERA OF PERSONALIZED MEDICINE IN PSYCHIATRY?
    Mueller, Daniel
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S717 - S718
  • [40] A new era of personalized medicine for cystic fibrosis - at last!
    Quon, Bradley S.
    Wilcox, Pearce G.
    [J]. CANADIAN RESPIRATORY JOURNAL, 2015, 22 (05) : 257 - 260